Group 1 - Johnson Fistel, PLLP has initiated an investigation into the board members of Integral Ad Science Holding Corp. (IAS) regarding potential breaches of fiduciary duties related to the proposed sale to Novacap [1] - The proposed acquisition price is $10.30 per share, which is significantly lower than the average Wall Street analyst price target of $13.04 per share, with some targets reaching as high as $18.00 per share [7] - IAS's initial public offering was priced at $18.00 per share, indicating that the proposed sale undervalues the company [7] Group 2 - Shareholders who believe the proposed deal undervalues their investment are encouraged to join the investigation [3] - Johnson Fistel, PLLP is recognized as a leading law firm in securities fraud and investor rights, with a history of recovering significant amounts for clients [5] - The firm has been ranked among the Top 10 Plaintiff Law Firms in 2024, having recovered approximately $90.725 million for clients in various cases [5]

Core Viewpoint - Johnson Fistel, PLLP is investigating potential legal claims on behalf of Capricor Therapeutics, Inc. shareholders regarding alleged misconduct by certain officers and directors that may have harmed the company and its investors [1]. Group 1: Legal Investigation - The investigation focuses on potential legal claims related to misconduct by Capricor's officers and directors [1]. - Investors who held Capricor shares since before October 9, 2024, may have legal rights and are encouraged to contact Johnson Fistel for more information [2]. Group 2: Company Background - Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, and Colorado [3]. - The firm has recovered over $90 million for clients and is recognized among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services [3].

SAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, has launched an investigation into whether the board members of Metsera, Inc. (NASDAQ: MTSR) breached their fiduciary duties in connection with the proposed sale of the Company to Pfizer, Inc. (NYSE: PFE). Background: On September 21, 2025, Metsera and Pfizer entered into a definitive merger agreement. Under the terms of the agreement, holders of Metsera’s common stock will receive $47.50 per share in cash. In a ...

Group 1 - The Gross Law Firm has issued a notice to shareholders of Unicycive Therapeutics, Inc. regarding potential legal matters [1]

Core Insights - Telix Pharmaceuticals Limited experienced a significant decline in the price of its American Depositary Shares (ADS), falling approximately 16% after the FDA requested additional data for its kidney cancer detection drug [1] - The company had previously faced a 10% drop in ADS price following the announcement of a subpoena from the SEC regarding its disclosures related to prostate cancer therapeutic candidates [1][3] Company Developments - On August 28, 2025, Telix received a Complete Response Letter (CRL) from the FDA for its Biologics License Application for Zircaix, which is intended for diagnosing clear cell renal cell carcinoma [3] - The CRL highlighted deficiencies in chemistry, manufacturing, and controls, and requested further data to establish comparability between the drug product used in clinical trials and the intended commercial manufacturing process [3] - The FDA also issued notices of deficiency to Telix's third-party manufacturing and supply chain partners, which need to be addressed [3] Legal and Investigative Actions - Hagens Berman, a national shareholders rights firm, is investigating whether Telix misled investors regarding its drug candidates and their development [2][4] - The investigation is particularly focused on the company's statements about its prostate cancer therapeutic candidates and the kidney cancer detection drug [2][4] - Investors who have suffered substantial losses are encouraged to submit their losses to assist in the investigation [2][4]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Ready Capital Corporation due to a class action complaint alleging breaches of fiduciary duties by the company's board of directors during a specified class period [1][2]. Group 1: Legal Investigation - The law firm is encouraging long-term stockholders of Ready Capital who suffered losses between November 7, 2024, and March 2, 2025, to discuss their legal rights [1]. - A class action complaint was filed on March 6, 2025, alleging that the board made materially false and misleading statements regarding the company's business and operations [2]. Group 2: Allegations Against Ready Capital - The complaint claims that significant non-performing loans in Ready Capital's commercial real estate (CRE) portfolio were unlikely to be collectible, which was not disclosed to investors [2]. - It is alleged that Ready Capital would fully reserve these problem loans to stabilize its CRE portfolio, and this was not accurately reflected in the company's expected credit loss or valuation allowances [2]. - As a result of these undisclosed issues, the company's financial results were adversely affected, and the positive statements made by the defendants were misleading [2].

Core Viewpoint - MediaAlpha, Inc. is facing legal scrutiny due to allegations of consumer deception and misconduct related to its marketing practices, leading to a settlement with the FTC involving a $45 million fine [2]. Group 1: Legal Issues - Julie & Holleman LLP is investigating potential misconduct by MediaAlpha's directors and officers in light of recent litigation from the FTC [1]. - The FTC charged MediaAlpha with deceiving consumers into purchasing health care plans that did not deliver the promised coverage and overwhelming them with telemarketing and robocalls [2]. - MediaAlpha agreed to settle the FTC's claims by paying a fine of $45 million on August 6, 2025 [2]. Group 2: Firm Information - Julie & Holleman LLP specializes in shareholder litigation, including derivative actions, mergers and acquisitions cases, securities fraud class actions, and corporate investigations [4]. - The firm has a track record of securing hundreds of millions of dollars for aggrieved companies and their shareholders [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Hims & Hers Health, Inc. due to a class action complaint alleging breaches of fiduciary duties by the company's board of directors during a specified class period [1][2]. Group 1: Legal Investigation - The law firm is representing long-term stockholders of Hims & Hers who held shares between April 29, 2025, and June 23, 2025, and is encouraging them to discuss their legal rights [1][3]. - A class action complaint was filed on June 25, 2025, concerning the alleged misleading statements and omissions made by the company during the class period [1][2]. Group 2: Allegations Against Hims & Hers - The lawsuit claims that Hims & Hers made false statements regarding its collaboration with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy for its subscribers [2]. - Specific allegations include that Hims & Hers misrepresented the approval of its compounded semaglutide products and the partnership with Novo, which purportedly misled investors and led to a significant decline in the company's stock value [2].

Core Viewpoint - Johnson Fistel, PLLP has initiated an investigation into potential breaches of fiduciary duties by the board members of Verint Systems Inc. regarding the proposed sale to Thoma Bravo, which is perceived to undervalue the company significantly [1][6]. Company Overview - Verint Systems Inc. has entered into a definitive merger agreement with Thoma Bravo, where shareholders will receive $20.50 in cash per share [6]. - The proposed merger price is notably lower than Verint's 52-week high of $34.80 per share, despite positive projections from Wall Street analysts regarding the company's sales and revenue growth [6]. Legal Context - Johnson Fistel, PLLP is a recognized shareholder rights law firm that represents both individual and institutional investors in derivative and class action lawsuits [3]. - The firm has a history of recovering significant amounts for clients, having secured approximately $90.725 million in 2024 for aggrieved clients [4].

Core Viewpoint - The law firm Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Guess?, Inc. to Authentic Brands Group for $16.75 per share, which is significantly lower than its 52-week high of $21.81, indicating a potentially opportunistic acquisition [1][4]. Group 1: Sale Details - Guess? has agreed to be sold for $16.75 per share in cash to Authentic Brands Group [4]. - The sale price is notably below Guess?'s 52-week high of $21.81 per share, raising concerns about the fairness of the transaction [1][4]. Group 2: Shareholder Concerns - Certain existing shareholders, including co-founders and the CEO, will roll over their shares into equity interests in the post-close entity, a benefit not extended to public stockholders [2][5]. - The sale was approved by a Special Committee of the Board, which may have conflicts of interest affecting its members [3][6]. Group 3: Investigation Focus - The investigation by Wohl & Fruchter LLP aims to determine if the Special Committee acted in the best interests of Guess? shareholders, including the independence of its members and the fairness of the sale price [7].